Oramed reports nine-month 2025 net income of $65M, up from loss of $6.1M

ORAMED PHARMACEUTICALS INC.

2025-Q3 EPS reported $1.26 revenue$2,000,000

Net income (pre-tax) of $65.0M vs. $6.1M loss; basic EPS $1.30, diluted $1.26.
Full $100M repayment from Scilex completed; $27M received in the period.
Total assets up 42% to $220.5M; driven by cash returns and unrealized gains on Alpha Tau (DRTS).
R&D expenses fell to $4.4M from $4.9M; G&A rose to $5.0M from $4.3M.
Unrealized fair-value gains on equity holdings in Alpha Tau and other investments contributed to income.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.